The fact that AEBP1 is necessary for cellular viability in both PTEN-proficient and PTEN-deficient tumor cells, suggests that AEBP1 can be a good potential target for therapeutic intervention in glioma patients in general irrespective of the PTEN status. This evidence concerns the gene PTEN and central nervous system cancer.